Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Collaboration enables Brenntag to serve pharma customers in EMEA with chromatography silica gels
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Phase 3 data expected in the second half of 2024
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
Dr. Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation
The collaboration brings a seamless digital experience to more formulators worldwide
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
